= Orders Today will be Shipped Tomorrow

	TOP 4 REASONS = TO BUY WSCH

The products and medical therap= ies developed by WSCH represent possibly the most important breakthroug= h in the field of Dermatology in the last fifty years.
2.	WSCH anticipates FDA approval on seven over-the-counter= products within the next year, which will provide significant revenue in = the retail drug market.
3.	WSCH has experienced a= success rate of 90% during clinical studies, completely eliminatin= g skin disease from 90% of all patients treated.
4.	By year five, WSCH plans to have annualized revenue over $525 millio= n and over $125 million in EBIT. This does not take into = account income from OTC products which will be substantial. = ;
	= PROJECT= IONS, OBJECTIVES AND STATISTICS
&= nbsp; &nb= sp; = ; &= nbsp; &nb= sp; = ; Over a five year period, AISC (WSCH's subsidiary) plans to establi= sh 350 clinics in over 100 major population areas. The company= plans to hire over 150 medical doctors for these clinics, train over 1,00= 0 medical assistants and treat over 2,000,000 patients. Also by yea= r five, WSCH plans to have annualized over $525 million in revenue and = over $125 million in EBIT. This does not take into account income from= OTC products which will be substantial. As of 1991, there w= ere approximately 14 million chronic acne and eczema patients annua= lly in the United States, with the highest percentage between 18 to 4= 4 years of age. The actual number of patients with any type of acne&n= bsp;Is significantly higher. Seven billion dollars is spent a= nnually on dermatological pharmaceutical products for these disor= ders. In 1994, the teen population reached 25 million= . During the next decade, it will grow at nearly twice the rate of= the overall population (according to U.S. Census Bureau pro= jections). Acne patients are primarily teenagers, whereas eczema= patients range from infants to the elderly.

SYMBOL:	= ; WSCH
= &n= bsp; CURRENT PRICE:	<= /font>$0.059
&nb= sp; 52 WEEK HIGH:	$27.50
52 WEEK LOW:	= $0.0= 56

COMPANY BACKGROUND

Wasatch Pharmaceutical, Inc. is a fourteen ye= ar old company with a record of outstanding achievements in the field of D= ermatology. Dermatology. Under the name of its subsidiary, American I= nstitute of Skin Care (AISC), Wasatch has operated two prototype cl= inics for the last five years where the products and medical therapies hav= e been tested and proven on hundreds of patients. The Company's activities= have been centered on research in the area of serious skin diseases. A concurrent discovery and benefit = is WSCH's dramatic success in the area of skin rejuvenation.

Seeing the high growth potential from major funding, WSC= H elected to become a public company less than two years ago.

Wasatch's major successes in the area o= f skin diseases include:

Cystic Acne, Ec= zema, Seborrhea, Contact Dermatitis, Molluscum, Folliculitis, Acne Rosacea= and less prevalent skin diseases.

Inte= restingly, these skin disorders account for more than 70% of all busine= ss in the field of dermatology for which there are very few (if any) s= afe, effective therapies like those developed by Wasatch.

Because the therapies developed by Wasatch domina= te this area of medicine, WSCH has elected to market its products via = company-owned clinics throughout the United States. This decision has= resulted in the establishment of two research clinics in Utah for = the purpose of implementing procedures within the clinics pursuant to test= ing and confirming the results that were achieved in past clinical trials.= Due to its success rate of 90% on hundreds of patients over a f= ive year period, WSCH's clinics are now on line with insurance provide= rs independent of HMOs. Efforts to establish Preferred Providership status= with HMOs are presently being pursued.

마음이 울적하고 누군가 그리울때 24시간 기다리고 있어요

Wasatch Pharmaceutical Inc. Announ= ces a New Physician Marketing Campaign and Listing On German Stock Exchang= es

교통사고 보상상담 안내